BMO
TEVA icon

Beck Mack & Oliver’s Teva Pharmaceuticals TEVA Stock Holding History

Beck Mack & Oliver’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-620,000
Closed -$5.65M – 172
2022
Q4 		$5.65M Buy
+620,000
New +$5.41M 0.17% 64
2022
Q3 		– Sell
-7,350
Closed -$2.15M – 173
2022
Q2 		$2.15M Buy
7,350
+250
+4% +$2.18K 0.06% 86
2022
Q1 		$3.25M Buy
7,100
+2,590
+57% +$21.6K 0.08% 79
2021
Q4 		$1.63M Buy
4,510
+3,000
+199% +$27.1K 0.04% 97
2021
Q3 		$702K Hold
1,510
– – 0.02% 133
2021
Q2 		$891K Hold
1,510
– – 0.02% 118
2021
Q1 		$770K Hold
1,510
– – 0.02% 118
2020
Q4 		$819K Hold
1,510
– – 0.03% 117
2020
Q3 		$725K Sell
1,510
-2,448
-62% -$25.9K 0.03% 121
2020
Q2 		$1.37M Buy
3,958
+2,658
+204% +$30.1K 0.05% 92
2020
Q1 		$712K Sell
1,300
-1,808
-58% -$18.5K 0.03% 115
2019
Q4 		$475K Buy
+3,108
New +$27.7K 0.02% 149
2019
Q3 		– Sell
-2,235
Closed -$226K – 219
2019
Q2 		$226K Buy
+2,235
New +$26.9K 0.01% 198

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Beck Mack & Oliver's TEVA Position: Q2 2026 in Review

Beck Mack & Oliver increased its Teva Pharmaceuticals (TEVA) stake by 0.54% in Q2 2026, buying an estimated $189K and bringing the position to 1,057,375 shares worth $35.8M. The position accounts for 0.7% of the portfolio, ranked #35.

Beck Mack & Oliver first reported a position in TEVA in Q2 2013 and has held it in 42 quarters since. The position peaked at $71.7M in Q3 2021. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Beck Mack & Oliver held 1,057,375 shares of Teva Pharmaceuticals worth $35.8M as of Q2 2026.
  • Beck Mack & Oliver bought 5,675 Teva Pharmaceuticals shares in Q2 2026, an estimated $189K.
  • Teva Pharmaceuticals made up 0.7% of Beck Mack & Oliver's portfolio in Q2 2026, its #35 holding.
  • Beck Mack & Oliver first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 42 quarters since.
  • Beck Mack & Oliver's Teva Pharmaceuticals position peaked at $71.7M in Q3 2021.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Beck Mack & Oliver's 13F filing for Q2 2026, filed 14 Aug 2026.